Lates News

Every AI Express, Huatai Securities released a research report on August 11th, giving Sannxin Medical (300453.SZ) a buy rating. The main reasons for the rating include: 1) Overseas markets continue to grow rapidly, with a growth rate of about 67% in the first half of 2025; 2) The core business of blood purification maintains high-speed growth, with a growth rate of about 20% in the first half of 2025; 3) Plans to issue convertible bonds of 530 million yuan for continuous capacity expansion. (Daily Economic News)